Balkan Journal of Medical Genetics

ASSOCIATION OF THE APOLIPOPROTEIN A-I GENE POLYMORPHISMS WITH CARDIOVASCULAR DISEASE RISK FACTORS AND ATHEROGENIC INDICES IN PATIENTS FROM ASSAM, NORTHEAST INDIA
Bora K1,2,*, Pathak MS2, Borah P3, Hussain Md.I.3, Das D4
*Corresponding Author: : Dr. Kaustubh Bora, Regional Medical Research Centre, Northeast Region, Indian Council of Medical Research (ICMR), P.O. Box 105, Dibrugarh-786001, Assam, India. Tel: +91-943-557-2062. Fax: +91-364-253-8003. E-mail: kaustubhbora1@gmail.com
page: 59

REFERENCES

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics – 2015 update: A report from the American Heart Association. Circulation. 2015; 131(4): e29e322. doi: 10.1161/CIR.0000000000000152. 2. Remaley AT, Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins and cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE, Eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 5th ed., 1st Indian reprint. New Delhi, India: Elsevier (Reed Elsevier India Pvt. Ltd.). 2012: 731-805. 3. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18): 1837-1847. 4. Dallinga-Thie GM, Bu XD, Trip MLS, Rotter JI, Lusis AJ, de Bruin TWA. Apolipoprotein A-I/C-III/A IV gene cluster in familial combined hyperlipidemia: Effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res. 1996; 37(1): 136-147. 5. Wojciechowski AP, Farrall M, Cullen P, Wilson TME, Bayliss JD, Farren B, et al. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23q-q24. Nature. 1991; 349(6305): 161-164. 6. de Franca E, Alves JG, Hutz MH. APOA1/C3/A4 gene cluster variability and lipid levels in Brazilian children. Braz J Med Biol Res. 2005; 38(4): 535-541. 7. Ding Y, Zhu MA, Wang ZX, Zhu J, Feng JB, Li DS. Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome. J Biomed Biotechnol. 2012; 2012: 509420. doi: 10.1155/2012/509420. 8. Swanson CR, Li K, Unger TL, Gallagher MD, van Deerlin VM, Agarwal P, et al. Lower plasma apolipoprotein A1 levels are found in Parkinson’s disease and associate with apolipoprotein A1 genotype. Mov Disord. 2015; 30(6): 805-812. 9. Smach MA, Edziri H, Charfeddine B, Ben Othman L, Lammouchi T, Ltaief A, et al. Polymorphism in apoA1 influences high-density lipoprotein cholesterol levels but is not a major risk factor of Alzheimer’s disease. Dement Geriatr Cogn Disord Extra. 2011; 1(1): 249-257. 10. Liu ZH, Xiao YM, Tang LY, Jiang L, Wang YJ, Zhang RC, et al. Apolipoprotein A1 -75 G/A and +83 C/T polymorphisms and renal cancer risk. Lipids Health Dis. 2015; 14: 143. doi: 10.1186/s12944-015-0132-0. 11. Hsu MC, Lee KT, Hsiao WC, Wu CH, Sun HY, Lin IL, et al. The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: A 10-year follow-up study. BMC Cancer. 2013; 13: 330. doi: 10. 1186/1471-2407-13-330. 12. Miroshnikova VV, Rodygina TI, Demina EP, Kurjanov PS, Urazgildeeva SA, Gurevich VS, et al. Association of apoprotein A-1 genetic variants with development of atherosclerosis in the population of St. Petersburg. Russian J Genet Appl Res. 2011; 1: 411-415. doi: 10.1134/ S207905971105011X. 13. Coban N, Onat A, Guclu-Geyik F, Komurcu-Bayrak E, Can G, Erginel-Unaltuna N. Gender-specific associations of the APOA1 -75G>A polymorphism with several metabolic syndrome components in Turkish adults. Clin Chim Acta. 2014; 431: 244-249. doi: 10.1016/j.cca. 2014.01.017. 14. Souverein OW, Jukema JW, Boekholdt SM, Zwinderman AH, Tanck MWT. Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD. Eur J Hum Genet. 2005; 13(4): 445-451. 15. Wang XL, Badenhop R, Humphrey K, Wilcken DE. New MspI polymorphism at +83 bp of the human apolipoprotein A1 gene: Association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol. 1996; 13(1): 1-10. 16. Dawar R, Gurtoo A, Singh R. Apolipoprotein A1 gene polymorphism (G-75A and C+83T) in patients with myocardial infarction: A pilot study in a North Indian population. Am J Clin Pathol. 2010; 134(2): 249-255. 17. Liao BH, Cheng KQ, Dong SH, Liu HD, Xu ZL. Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease. Diagn Pathol. 2015; 10: 102. doi: 10.1186/s13000015-0328-7 18. Kim YR, Hong SH. The apolipoprotein A1 polymorphisms were associated with decreased risk for metabolic syndrome in Koreans. Genes Genome. 2015; 37(10): 875-882. doi: 10.1007/s13258-0150318-x. 19. Pagani F, Sidoli A, Giudichi GA, Barenghi L, Vergani C, Baralle FE. Human apolipoprotein A-I gene promoter polymorphism: Association with hyperalphalipoproteinemia. J Lipid Res. 1990; 31(8): 1371-1377. 20. Wang XL, Badenhop R, Humphrey K, Wilcken DEL. C to T and G to A transitions are responsible for loss of a MspI restriction site in the 59-region of the human apolipoprotein AI gene. Hum Genet. 1995; 95(4): 473-475. 21. Bora K, Pathak MS, Borah P, Hussian MI, Das D. Single nucleotide polymorphisms of APOA1 gene and their relationship with serum apolipoprotein A-I concentrations in the native population of Assam. Meta Gene. 2016; 7: 20-27. doi: 10.1016/j. mgene.2015.10.005. 22. Bora K, Pathak MS, Borah P, Das D. Variation in lipid profile across different patterns of obesity – Observations from Guwahati, Assam. J Clin Diagn Res. 2015; 9(11): OC17-OC21. 23. Kotokey R, Hazarika S, De A. Lipid abnormalities in hypertensive urban population of Dibrugarh district of upper Assam. Indian Heart J. 2006; 58(6): 405-408. 24. Gururaj G, Girish N, Isaac MK. Mental, neurological and substance abuse disorders: Strategies towards a systems approach. In: National Commission on Macroeconomics and Health (NCMH) Background Papers – Burden of disease in India. New Delhi, India: NCMH, Ministry of Health & Family Welfare, Government of India. 2005: 226-250. 25. National Cardiovascular Disease Database. Ministry of Health & Family Welfare, Government of India and World Health Organisation. http://www.searo.who. int/ india/topics/cardiovascular_diseases/NCD_Resources_National_CVD_database-Final_Report.pdf. (Last accessed on June 21 2016.) 26. Shah SK, Saikia M, Snehlata C, Ramachandran A. High prevalence of type 2 diabetes in urban population of north eastern India. Int J Diabetes Dev Countries. 1999; 19: 144-147. 27. Ridkar PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-1 and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005; 294(3): 326-333. 28. Pereira T. Dyslipidemia and cardiovascular risk: lipid ratios as risk factors for cardiovascular disease. In: Kelishandi R, Ed. Dyslipidemia – From Prevention to Treatment. Rijeka, Croatia: InTech Europe. 2012: 279-302. 29. Kennel WB. Risk stratification of dyslipidemia: Insights from the Framingham Study. Curr Med Chem Cardiovasc Hematol Agents. 2005; 3(3): 187-193. 30. National Cholesterol Education Program. Third and Final report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002; 106(25): 3143-3421. 31 World Health Organisation. Annex 2: Recom-mended measurement protocols and derivation of indices. In: World Health Organisation Technical Report Series 854, Physical Status: The Use and Interpretation of An-thropometry. Geneva, Switzerland: World Health Organisation, 1995: 424-438. 32. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003; 289(19): 2560-2572. 33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the low-density lipoprotein cholesterol concentration in plasma without the use of preparative centrifuge. Clin Chem. 1972; 18(6): 499-502. 34. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983; 67(4): 730-734. 35. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted-plasma (FERHDL). Clin Biochem. 2001; 34(7): 583-588. 36. Nunes SOV, de Melo LGP, de Castro MRP, Barbossa S, Vargas HO, Berk M, et al. Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. J Affect Disord. 2015; 172: 55-62. doi: 10.1016/j. jad.2014.09.038. 37. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. New York, NY, USA: Routledge Academic, 1969. 38. Al-Bustan SA, Al-Serri AE, Annice BG, Alnaqeeb MA, Ebrahim GA. Re-sequencing of the APOAI promoter region and the genetic association of the -75G>A polymorphism with increased cholesterol and low density lipoprotein levels among a sample of the Kuwaiti population. BMC Med Genet. 2013; 14: 90. doi: 10.1186/1471-2350-14-90. 39. Saha N, Tay JS, Low PS, Humphries SE. Guanidine to adenine (G/A) substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI levels in Chinese non-smokers. Genet Epidemiol. 1994; 11(3): 255264. 40. Qingwei Z, Mingpeng S, Ping S, Hua Z, Mengling Z. Interaction of alcohol and G to A substitution at the promoter region of apolipoprotein AI gene in determining plasma apolipoprotein AI levels in Yi and Han Chinese. Chinese Med J. 2000; 113(5): 471-474. 41. Li Y, Yin R, Zhou Y, Deng Y, Yang D, Pan S, et al. Associations of the apolipoprotein A-I gene polymorphism and serum lipid levels in the Guangxi Hei Yi Zhuang and Han populations. Int J Mol Med. 2008; 21(6): 753-764. 42. Kessling AM, Horsthempke B, Humphries SE. A study of DNA polymorphism around the human apolipoprotein AI gene in hyperlipidaemic and normal individuals. Clin Genet. 1985; 28(4): 296-306. 43. Ma YQ, Thomas GN, Tomlinson B. Association of two apolipoprotein A-I gene MspI polymorphisms with lipid and blood pressure levels. Int J Cardiol. 2005; 102(2): 309-314.

Number 27 VOL. 27 (2), 2024	Number 27 VOL. 27 (1), 2024
Number 26 Number 26 VOL. 26(2), 2023 All in one	Number 26 VOL. 26(2), 2023
Number 26 VOL. 26, 2023 Supplement	Number 26 VOL. 26(1), 2023
Number 25 VOL. 25(2), 2022	Number 25 VOL. 25 (1), 2022
Number 24 VOL. 24(2), 2021	Number 24 VOL. 24(1), 2021
Number 23 VOL. 23(2), 2020	Number 22 VOL. 22(2), 2019
Number 22 VOL. 22(1), 2019	Number 22 VOL. 22, 2019 Supplement
Number 21 VOL. 21(2), 2018	Number 21 VOL. 21 (1), 2018
Number 21 VOL. 21, 2018 Supplement	Number 20 VOL. 20 (2), 2017
Number 20 VOL. 20 (1), 2017	Number 19 VOL. 19 (2), 2016
Number 19 VOL. 19 (1), 2016	Number 18 VOL. 18 (2), 2015
Number 18 VOL. 18 (1), 2015	Number 17 VOL. 17 (2), 2014
Number 17 VOL. 17 (1), 2014	Number 16 VOL. 16 (2), 2013
Number 16 VOL. 16 (1), 2013	Number 15 VOL. 15 (2), 2012
Number 15 VOL. 15, 2012 Supplement	Number 15 Vol. 15 (1), 2012
Number 14 14 - Vol. 14 (2), 2011	Number 14 The 9th Balkan Congress of Medical Genetics
Number 14 14 - Vol. 14 (1), 2011	Number 13 Vol. 13 (2), 2010
Number 13 Vol.13 (1), 2010	Number 12 Vol.12 (2), 2009
Number 12 Vol.12 (1), 2009	Number 11 Vol.11 (2),2008
Number 11 Vol.11 (1),2008	Number 10 Vol.10 (2), 2007
Number 10 10 (1),2007	Number 9 1&2, 2006
Number 9 3&4, 2006	Number 8 1&2, 2005
Number 8 3&4, 2004	Number 7 1&2, 2004
Number 6 3&4, 2003	Number 6 1&2, 2003
Number 5 3&4, 2002	Number 5 1&2, 2002
Number 4 Vol.3 (4), 2000	Number 4 Vol.2 (4), 1999
Number 4 Vol.1 (4), 1998	Number 4 3&4, 2001
Number 4 1&2, 2001	Number 3 Vol.3 (3), 2000
Number 3 Vol.2 (3), 1999	Number 3 Vol.1 (3), 1998
Number 2 Vol.3(2), 2000	Number 2 Vol.1 (2), 1998
Number 2 Vol.2 (2), 1999	Number 1 Vol.3 (1), 2000
Number 1 Vol.2 (1), 1999	Number 1 Vol.1 (1), 1998

About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact